Multiple Sclerosis & Immune Disorders

Filter Your Results

 

News

 

FDA Greenlights Two Generic Glatiramer Acetate Formulations for Relapsing MS

Wednesday, October 04, 2017—The FDA approved Mylan’s generic versions of glatiramer acetate, including a three-times weekly 40mg/mL formulation of glatiramer acetate and a once-…

Vitamin D Levels Tied to Risk of MS

Thursday, September 14, 2017—Examining vitamin D levels in the blood may help predict whether a person is at risk of developing multiple sclerosis (MS), according to a large new study published Neurology&…

Project ALS and Amylyx Team Up to Test Phase 2 Compound

Thursday, September 07, 2017—Project ALS and Amylyx Pharmaceuticals are collaborating to undertake pre-clinical studies to advance the understanding of Amylyx's oral compound AMX0035 for the treatment…

CLARITY Extension: Annual Short-Course Therapy with Investigational Oral Agent Effective in Relapsing MS

Tuesday, September 05, 2017—New results suggest that patients with relapsing multiple sclerosis (MS) treated with two annual short courses of the investigational cladribine tablets (EMD Serono) may have …

Gut Bacteria May Play Preventive Role in MS

Tuesday, August 15, 2017—New findings support the increasingly prominent hypothesis that gut bacteria play a role in autoimmune diseases such as multiple sclerosis (MS). Specifically, a study publishe…

Recently Approved ALS Treatment Radicava Now Available

Tuesday, August 08, 2017—Radicava (edaravone, Mitsubishi Tanabe Pharma America), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), is now avai…

Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial

Tuesday, May 23, 2017—New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way…

FDA Greenlights First New Treatment for ALS in More than Two Decades

Friday, May 05, 2017—The FDA has approved Radicava (edaravone, MT Pharma), as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS). Radicava is the first treatment approv…

 
 

Contact Info

For advertising rates and opportunities:
Wendy Terry
Publisher
217-652-3859
wterry@bmctoday.com

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.

 
  • BRYN MAWR COMMUNICATIONS III, LLC